GlassScriptPhysician profile
Matthew P Spinn
NPI 1598873705
$4,070.07
in general payments reported to CMS, 2019-2025
33 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $398 · 2021: $855 · 2022: $1,086 · 2023: $505 · 2024: $160 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.02 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $386.68 | 2019-2022 | |
| Celgene Corporation | $293.95 | 2021-2023 | Zeposia |
| Pfizer INC. | $285.16 | 2019-2025 | |
| Janssen Biotech, INC. | $284.09 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.32 | 2019-2025 | Trulance, Xifaxan |
| Allergan, INC. | $179.50 | 2019-2020 | |
| Perspectum Diagnostics LTD | $178.29 | 2022 | |
| Boston Scientific Corporation | $160.43 | 2019-2024 | Acquire |
| Braintree Laboratories, INC. | $114.41 | 2020-2025 | Sutab, Suflave |
| Qol Medical, LLC | $103.71 | 2019-2023 | Sucraid |
| Genzyme Corporation | $98.37 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $82.86 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.75 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $65.23 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $59.34 | 2021-2022 | |
| Gilead Sciences, INC. | $57.81 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $50.62 | 2019-2023 | Linzess |
| Lilly USA, LLC | $50.49 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $32.29 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $29.42 | 2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $24.80 | 2023 | |
| Evoke Pharma, INC. | $24.46 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.26 | 2020 | |
| Celltrion USA INC. | $22.81 | 2024 | Vegzelma |
| Madrigal Pharmaceuticals | $19.71 | 2025 | Rezdiffra |
| Medtronic, INC. | $18.80 | 2025 | Barrx |
| Aimmune Therapeutics, INC. | $17.30 | 2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $17.15 | 2021 | |
| Redhill Biopharma INC. | $17.10 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.25 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.29 | 2019 | |
| Intra-Sana Laboratories | $9.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Spinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.